glp-1 coverage news today insurers The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Massachusetts joins insurers cutting coverage

In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)

These medications also have potential serious side effects, like pancreatitis, gallbladder issues, and thyroid tumors, so any history of these conditions is a direct contraindication for prescribing, says Dr

In their study on GLP-1 and cholesterol homeostasis, Yao et al

However, sometimes those activities do not work on their own

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut that plays a key role in appetite regulation, insulin signalling and blood sugar balance

Dimidi E